COMPARATIVE ANTIHYPERTENSIVE PROPERTIES OF AQUEOUS EXTRACTS OF LEAVES, STEM BARK AND ROOTS OF HURA CREPITANS (L) IN ADRENALINE INDUCED HYPERTENSIVE ALBINO RATS.

Adindu Eze Azuibu1*, Elekwa Iheanyichukwu1, Okereke Stanley1 and Ogwo Joseph I.2
1Department Of Biochemistry, Abia State University, Uturu, Abia State Nigeria.
2Xtrim Research Laboratories, Aba, Abia State, Nigeria.
ezeadindu42@gmail.com

Abstract— The objective of this study was to investigate and compare the antihypertensive properties of the different parts (leaves, stem bark and roots) of Hura crepitans with a known standard antihypertensive drug-Propanolol. There were six animal groups of five animals each and their body weights were measured before, after induction and after treatment. All the groups were induced with hypertension with 0.1ml of adrenaline for 7 consecutive days except group 1, which acted as the normal control normotensive rats (NR). Group 2 consisted of hypertensive untreated rats (HUR); Group 3 consisted of propanolol treated hypertensive rats (PTHHR); Group 4 consisted of aqueous leaf extract treated hypertensive rats (LTHR); Group 5 consisted of stem bark treated hypertensive rats (BTHR); and Group 6 consisted of aqueous root treated hypertensive rats (RTHA). All the treated groups were administered with equal doses of 500mg/kg of the different plant extracts through oral gavage, except group 3 that was administered with 0.65mg/kg of propanolol. Water and commercial rat feed were given ad libitum. The treatment lasted for 14 days. Effects of the different extracts on different biochemical parameters such as body weight (BW), pulse rate (PR), serum creatinine, phosphokinase activity (CPA), Lactate Dehydrogenase Activity (LDHA), some liver enzymes (ALT & AST) and lipid profile (total Cholesterol (TC), Triglycerides (TG) Low Density Lipoprotein-Cholesterol (LDLC), High Density Lipoprotein (HDL) & Very Low Density Lipoprotein-Cholesterol (VLDLC). They were evaluated at various stages: pre-induction, post-induction and post-treatment. All the animals gained weight significantly (P<0.05). A significant decrease in pulse rate after treatment was recorded in all the treated animal groups when compared with UHA. All the treated animals showed significant decrease (P<0.05) in both ALT and AST activities. There was also significant decrease in LDHA in all the treated animal groups. In the LTHR, CPA increased significantly, while the other groups recorded non-significantly decrease in CPA. A significant decrease was recorded in TC in PTHR, LTHR and RTHR. TG and HDL decreased significantly in the treated animal groups. LDL decreased significantly in all the animal groups. There was also a significant decrease in VLDLC. These results suggest that the aqueous extracts of the different parts Hura crepitans possess hypertensive properties.

Index terms— Hura crepitans, anti-hypertension, pulse rate, body weight, lipid profile, creatine phosphokinase, lactate dehydrogenase, Alanine Amino Transaminase, Aspartate Amino Transaminases

I. INTRODUCTION

Hypertension or high blood pressure is a chronic medical condition resulting to elevated blood pressure in the arteries assessed by systolic and diastolic measurements (Lifton et al, 2001). The European society of Cardiology has defined hypertension as systolic values above 140mmHg and diastolic values above 90mmHg. However, these values are affected by age, sex and size (Giuseppe and Robert, 2013).

Hypertension is classified as primary/essential and secondary. Primary hypertension results from no obvious underlying medical cause and accounts for 90-95% of all cases of hypertension but results from a complex interaction of genes and environmental factors (Carretero, et al, 2000). Secondary hypertension results from identifiable causes such as: renal disease, endocrine condition, obesity, pregnancy, etc. (Beevars, 1998; Grossman, et al, 2012).

Hypertension is referred to as a silent killer because in most cases, it does not manifest any symptoms or signs until complications develop in vital organs. However, the following symptoms may be associated with hypertension; dizziness, flushed facies, headache, fatigue, epistaxis, nervousness, cardiovascular and neurologic anomalies.

There are many treatment and management strategies of hypertension which include: lifestyle modifications (salt restriction, moderation of alcohol consumption, dietary changes, weight reduction, regular physical exercise, smoking cessation) and pharmacological therapy (Beta blockers, Diuretics, calcium antagonists, etc). (Elmer, et al, 2006; Graudal et al, 2014; Mente, et al, 2009, Fagard, 2011; WHO,2003; Mancia,et al, 2009).
The use of medicinal plants in developing countries for the treatment of various ailments has reached an estimated 3.5 million people (Balick and Cox, 1996). The non-availability and high cost of orthodox drugs have enhanced the reliance on medicinal plants in primary health care. The high incidence and morbidity of hypertension have led to various drugs and regimes being advocated for its control. Many new drugs have been introduced with better efficacy but with side effects. Recently, attention has been drawn towards herbal and mineral preparations, which are traditionally used as potential therapeutic agents in the prevention and management of cardiovascular diseases (Omale, et al, 2011).

_Hura crepitans_ (L) is classified taxonomically as follows:

- **Kingdom:** Plantae
- **Phylum:** Angiosperms
- **Sub-Phylum:** Eudicots
- **Class:** Rosids
- **Order:** Malpighiales
- **Family:** Euphorbiaceae
- **Genus:** Hura
- **Species:** crepitans

_Hura crepitans_ is also known as the sand box tree, possum wood or jabillo. Its igbo native name is “Ububu”. In the wild, the tree grows above 40m and the stem and main branches are densely spiny. In ancient times, _Hura crepitans_ bark extract was used to treat leprosy. It is also known to be used for centuries against eczema. Moreover, the yellowish milky juice secreted by the plant was an important ingredient used by Amerindians to poison their darts. The juice is rich in lectins, which display powerful haemagglutinating activity hence inhibiting protein synthesis (Barbieri, et al, 1983).

Modern clinical trials have discovered a wide range of therapeutic actions of remedies derived from the bark, leaves and seeds of this plant. While still green, the seeds have a strong purgative effect and so does the oil extracted from them when dried (Poswal and Akpa, 1991).

Certain substances included in the complex chemical structure of _Hura crepitans_ qualifies this plant, thanks to its combined astringent and emollient actions, for dermatological use against various skin diseases (David, et al, 2014).

It has been shown that _Hura crepitans_’ seed oil has the potential for protection of cowpea seeds from _callosobruchus maculates_ fabricius infestation (Adedire and Ajayi, 2003). Recently, the work of David, et al, (2014) has equally shown the antimicrobial activities of essential oils from _Hura crepitans_. This showcases their essential oils as potential raw materials for the development of antimicrobial drugs by pharmaceutical industries against various microbial infections and or diseases.

### II. MATERIALS AND METHODS

#### A. Plant Material Collection

The plant materials used in this study were leaves, barks and roots of _Hura crepitans_ (Ububu, Possum wood, Jabillo, etc.) Fresh samples were harvested from the premises of University of Nigeria, Nsukka and sent to the plant science and Biotechnology Department of the same University for Identification.

#### B. Animal Model/ Induction/Treatment

About thirty (30) male and female Wister albino rats of between 8-10 weeks of age were randomly assigned to six (6) groups of five (5) animals per group and housed in stainless steel cage. The animals were exposed to the normal 12 hours light and dark cycle under tropical weather conditions. The animals were fed on commercial rat feed and water _ad libitum_.

All the groups were allowed to acclimatize for a period of one week. After the period of acclimatization, all the rats were anaesthetized with diethyl ether and 0.1ml of adrenaline was injected into the rats through intra-peritoneal injection using a 1ml disposable syringe daily for seven consecutive days in order to induce hypertension except control group. All the plant extract treated groups were treated with dose of the extract (500Mg/Kg).

The six groups were labelled as follows:

- **Group 1:** Normal control rats that received normal saline
- **Group 2:** Untreated adrenaline induced hypertensive rats
- **Group 3:** Positive Control group treated adrenaline induced hypertensive rats with Propanolol.
- **Group 4:** 500mg/kg leaf extract of _Hura crepitans_ treated adrenaline induced hypertensive rats
- **Group 5:** 500mg/kg bark extract of _Hura crepitans_ treated adrenaline induced hypertensive rats.
- **Group 6:** 500mg/kg root extract of _Hura crepitans_ treated adrenaline induced hypertensive rats.

The extracts were administered by oral gavage while the standard commercial drug (Propanolol) was administered through intra peritoneal (I.P) route once daily for two weeks.

#### C. Dose preparation of standard Antihypertensive Drug

The daily dose of propanolol for human is 45mg/70kg (Omale, et al, 2011). Therefore, a daily dose of 0.65mg/kg body weights of rats was administered through intra peritoneal injection.

#### D. PLANT DOSE PREPARATION

The different plant parts were pulverized into a fine powder using a pulverizer. 100g of the extract was put into 500ml of distilled water and vigorously shaken and allowed to settle for 24 hours. It was then filtered and dried in an oven in order to obtain the dry sample of the extract. 1g of the dry extract was dissolved in 10ml of distilled water in order to obtain 100mg/ml or 0.1g/ml.

#### E. Determination of Pulse Rate

The pulse rates of the animals were measured using the method described by Rod (2008). The femoral artery in the
groin on the medial aspect of the femur of the hind leg was used. The rats were restrained and once settled, the pulses were taken by placing finger over the femoral artery. The pulse rate was counted for one minute using a stop watch.

F. Body Weight Determination

The body weights of the rats were measured before induction of hypertension, after induction and after treatment using Kerro-BL20001 electronic weighing balance.

G. Determination of Serum Creatine Phosphokinase Activity

The activity of creatine phosphokinase was determined after 14 days of treatment according to the method described by Szasz et al., 1976 (Randox C.K. 110 kit was utilized for the quantitative in vitro determination of the enzyme in serum). 20ml of the sample was pipetted into a test tube and mixed with 1ml of the reagent (Randox C.K 110 kit). The mixture was left to incubate at 25°C for 3 minutes and the initial absorbance was read. The absorbance was taken again after 1, 2 and 3 minutes simultaneously at 340nm using an Agilent 8453 spectrophotometer. The creatine phosphokinase activity was calculated using the formulae;

\[ \text{LDH activity} = \frac{4127 \times \text{DA}}{340\text{nm/min}} \]

Where DA=Change in absorbance.

H. Determination of Serum Lactate Dehydrogenase Activity

The serum lactate dehydrogenase activity was determined after two weeks of treatment according to the method described by Weishaar, 1975. A portion (2ml) of the sample was pipetted into a test tube and mixed with 1.0 ml of reagent (Randox kit). After mixing, the initial absorbance was read after 30 seconds and again after 1, 2, 3 minutes simultaneously at 340nm using Agilent 8453 spectrophotometer. The lactate dehydrogenase activity was calculated using the following formula:

\[ \text{LDH activity} = \frac{9683 \times \text{DA}}{340\text{nm/min}} \]

Where DA=change in absorbance.

I. Lipid Profile

1) Total Cholesterol

This was determined using Randox Kit procedure as expressed by Akomas et al., (2014). In this method, 0.1ml of the serum was pipetted into a test tube and 1000μl of the Randox Cholesterol Reagent was added to it. The mixture was incubated for 10 minutes at 20 to 25°C and absorbance at wavelength 540nm was then read using a spectrophotometer against the reagent blank. The standard absorbance of 0.119 was equivalent to 200.65mg of cholesterol per dL of blood and was used to evaluate the test results.

2) Triglycerides

This was determined using Randox Kit procedures as expressed by Ijioma et al., (2014). In this method, 0.1ml of the serum was pipetted into test tube and 1000μl of the Randox triglyceride reagent added to it. The mixture was incubated for 10 minutes at 20-25°C. The absorbance of the sample and standard were measured using a spectrophotometer at wavelength 540nm against the reagent blank. The standard absorbance of 0.100 was equivalent to 196mg of triglycerides per dL of blood and was used to evaluate the test results.

3) High Density Lipoprotein cholesterol

This was determined Using Randox Kit procedures as expressed by Ijioma et al., (2014). In this method, O. I. of the serum was pipetted into a test tube and 1000μl of the Randox HDL-C reagent was added to it. The mixture was incubated for 10 minutes 1t 20-25°C. The absorbance of both the sample and standard were measured using spectrophotometer at wavelength 540nm against the reagent blank. A standard absorbance stipulated by the Kit producer of 0.307 = 202.65mg of HDL-C per dL of blood was used to evaluate the test results.

4) Low Density Lipoprotein cholesterol and very low Density Lipoprotein Cholesterol

Both were obtained by calculations using the formulae;

- LDL - C = Cholesterol - \[ \frac{\text{Triglycerides}}{5} \] + HDL
- VLDL – C = \[ \frac{\text{Triglycerides}}{5} \]

5) Determination of Alanine Amino Transaminase

The kit provides a rapid, simple, sensitive and reliable test suitable for high through put activity assay of ALT with a detection limit of 10mU per well.

Kit contents:.

- **Components**
  - ALT Assay Buffer
  - OxiRed™ in(DMSO)
  - ALT enzyme mix (lyophilized)
  - ALT substrate lyophilized
  - Pyruvate standard (100nmol/ul)
  - ALT positive control (lyophilized)

- **Cap code**
  - ALT Assay Buffer: Wm
  - OxiRed™ in(DMSO): 200ul
  - ALT enzyme mix (lyophilized): 1 vial
  - ALT substrate lyophilized: 1 vial
  - Pyruvate standard (100nmol/ul): Yellow
  - ALT positive control (lyophilized): Blue

- **Reagent preparation**

ALT enzyme mixed and reconstituted with 220ul dH2O. Aliquot was stored at -20°C.

ALT substrate reconstituted with1:1ml assay buffer. Aliquot was stored at -20°C.

ALT positive control: Reconstitute with 100ul dH2O. Aliquot was stored at -20°C. 5-10ul was added as positive control and adjusted to the final volume to 20ul/well ALT assay buffer.

**Standard Curve Preparation**

**Colorimeter assay:**

The pyruvate standard was diluted to 1nmol/ul by adding 10ul of the standard to 990ul of ALT assay buffer, and mixed well. 0-, 2, 4, 6, 8, 10ul were added into a series of standard wells. Volume was adjusted to 20ul/well with ALT assay buffer mixed with 10ul of the standard to 900ul of ALT assay buffer.
buffer to generate 0, 2, 4, 6, 8, 10nmol/well of the pyruvate standard for the colorimeter assay.

**Sample preparation**

Serum samples were diluted in assay buffer. Test samples of up to 20ul/well were prepared with assay buffer in a 96-well plate.

**Reaction Mix:** Enough reagents were mixed for the number of the number of assays to be performed. For each well, a total 100ul reaction mix was prepared.

- ALT Assay Buffer: 86ul
- Oxi Red Probe: 2ul
- ALT Enzyme mix: 2ul
- ALT Substrate: 10ul

100ul of the sample reaction mix was added to each well containing the samples, standard and positive control (optional) and mixed well.

**Measurement**

OD \(570\text{nm} (A_1)\) at \(T_1\) (\(T_1>10\text{min}\)) was read, then again (\(A_2\)) at \(T_2\) after incubating the reaction at 37°C for 60min (or longer if the ALT activity is low). It was protected from light. The OD of the colour generated by oxidation of pyruvate is \(\Delta A570\text{nm}=A_2-A_1\)

**Calculation**

The pyruvate standard curve was plotted and used; \(\Delta A570\text{nm}\) to obtain B (nmol) of pyruvate (amount of pyruvate generated \(T_1\) and \(T_2\) in the reaction wells)

ALT activity in the test sample was then be calculated:

\[
\text{ALT Activity} = \frac{(A_2-T_2) \times V}{(T_1-T_2) \times x} \times 1000 = \text{nmol/min/ml} = \text{mU/ml}
\]

Where B is the pyruvate standard curve (in nmol)

\(T_1\) is the time of the first reading (\(A_1\)) (in min)

\(T_2\) is the time of the second reading (\(A_2\)) (in min)

\(V\) is the original sample volume added into the reaction well (in ml).

One unit of ALT is defined as the amount of ALT which generates 1.0ul of pyruvate per minutes at 37°C.

### 6) Determination of Aspartate Transaminase

Kit was developed based on Bergmeyer (1974) method

**Kit Components**

- Assay Buffer: 24ml
- Co-factors: 120\(\mu\)l
- Enzyme mix: 120\(\mu\)l
- NADH: 500\(\mu\)l

**Materials**

- Pipetting devices and accessories
- Spectrophotometer and cuvettes for measuring OD\(_{340\text{nm}}\)

**Assay Procedure**

All components were equilibrated to room temperature and thawed enzymes were kept in ice. For each assay, one standard and one blank control were included. For each sample and standard, working reagent was prepared by mixing 1000ul assay buffer, 5\(\mu\)l cofactor, 5\(\mu\)l enzyme mix and 20\(\mu\)l NADH. Transfer 990\(\mu\)l working reagent to each sample cuvette and standard cuvette and warm to desired temperature (37°C). To blank control cuvette, 960\(\mu\)l assay buffer, 5\(\mu\)l cofactor, 5\(\mu\)l enzyme were added and mixed with 20\(\mu\)l H\(_2\)O; then warmed to desired temperature (37°C). Samples were pre-warmed to the desired temperature. 100 \(\mu\)l sample was added to the sample cuvette. 100\(\mu\)l H\(_2\)O was transferred to the standard cuvette and blank control cuvette respectively. Mix immediately and read OD\(_{340\text{nm}}\) and 10 minutes.

**Calculation**

Determination of AST activity using the following equation:

\[
\text{AST}\ = \frac{388\times \Delta OD_{570}-\Delta OD_{NADH}}{\text{U/L}}
\]

OD\(_{STD}\) and OD\(_{BLK}\) are the OD\(_{340\text{nm}}\) values of NADH standard and blank at 5 min. respectively. The factor 388 is derived from:

\[
\text{Factor} = 10 \text{ Mm NADH} \times 4\,\mu\text{mol NADH} \times 200\,\mu\text{vol. WR} \times 11\text{ sample density}
\]

\[
=206\mu\text{mol. WR} \times 220\mu\text{vol. Total 5min.} = 388\mu\text{M/min.}
\]

If the calculated AST activity is higher than 100\(\mu\)l dilute sample in assay buffer and repeat assay. Multiply results by the dilution factor.

7) **Statistical Analysis**

Data were expressed as mean ± SEM. One way analysis of Variance (ANOVA) followed by Benferonis multiple comparison test was applied. A probability value of 0.05 (\(P<0.05\)) was considered significant.

### III. Results and Discussion

Medicinal plants have gained much ground due to the following reasons: wide availability, cheap and affordability, little side effects, wide range of therapeutic applications as well as inadequate trained medical personnel’s and high cost of orthodox medicine (Bako, et al, 2010).

Table 1 shows the comparative body weights of non-hypertensive, untreated hypertensive rats and treated hypertensive rats. All the animals gained significant (\(P<0.05\)) weight throughout the experimental period. This increase in weight may be due to the effect of the extract and its nutritive value. This is because the proximate, elemental and fatty acid profile of \(H. crepitans\) have been shown to be rich in proteins, fatty acids and carbohydrates, which are necessary for energy, growth and repair (Oyeleke, et al, 2012; Alabi, et al, 2013). Also, the relative non-toxicity of the extract may have also contributed to weight gain as organ or tissue damage may result to weight loss. However, the balance commercial rat ration and water given ad libitum may be the principal contributor to weight gain.
Table 2: PULSE RATES OF TREATED HYPERTENSIVE RATS

<table>
<thead>
<tr>
<th>Groups</th>
<th>Pre Induction Body Weight</th>
<th>Post Induction Body Weight</th>
<th>Post Treatment Body Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre Induction</td>
<td>Post Induction</td>
<td>Post Treatment</td>
</tr>
<tr>
<td>1</td>
<td>229.4 ± 4.17</td>
<td>226.3 ± 3.90</td>
<td>221.80 ± 2.34</td>
</tr>
<tr>
<td>2</td>
<td>227.20 ± 5.95</td>
<td>286.60 ± 6.78</td>
<td>276.80 ± 6.22</td>
</tr>
<tr>
<td>3</td>
<td>224.00 ± 3.10</td>
<td>294.20 ± 4.08</td>
<td>239.80 ± 2.65</td>
</tr>
<tr>
<td>4</td>
<td>227.20 ± 5.95</td>
<td>286.00 ± 6.78</td>
<td>276.80 ± 6.22</td>
</tr>
<tr>
<td>5</td>
<td>234.6 ± 2.48</td>
<td>294.00 ± 2.61</td>
<td>235.60 ± 1.10</td>
</tr>
<tr>
<td>6</td>
<td>227.20 ± 5.95</td>
<td>286.00 ± 6.78</td>
<td>276.80 ± 6.22</td>
</tr>
<tr>
<td>7</td>
<td>234.4 ± 4.17</td>
<td>284.80 ± 3.14</td>
<td>237.00 ± 3.65</td>
</tr>
<tr>
<td>8</td>
<td>227.20 ± 5.95</td>
<td>286.00 ± 6.78</td>
<td>276.80 ± 6.22</td>
</tr>
<tr>
<td>9</td>
<td>232.4 ± 3.46</td>
<td>284.00 ± 3.14</td>
<td>232.40 ± 4.15</td>
</tr>
</tbody>
</table>

* The mean difference is significant at P<0.05 level.

The values in the columns are expressed as mean ± S.E.M., n=5

![Graph](image)

Fig 2: % Activity Effects of Pulse Rates
P1= Pre-Induction; P2= Post-Induction; P3= Post-Treatment

Table 3 shows the activities of Alanine Amino Transaminase (ALT) and Aspartate Amino Transaminase (AST) at the pre-induction, post-induction and post-treatment stages. At the post-induction stages, the activities of both ALT and AST increased significantly (P<0.05) when compared with the normal control animals. However, a significant decrease (P<0.05) was recorded in all the treated animals (propanolol and plant extract treated) when compared with the untreated hypertensive animals. Increased level of ALT and AST suggests heart or liver damage. This decrease recorded suggests possible amelioration of cardiovascular risk by the different aqueous extracts.
The activities of lactate dehydrogenase (LDH) and creatine phosphokinase (CPA) are shown in Table 4. The results show a significant increase in the activities of both LDH and CPA at the post-induction stage when compared with the normal control groups. At the post-treatment stage, LDH activity decreased in all the groups, when compared with the untreated hypertensive rats. Activities of CP decreased in all the treated groups except in the group treated with aqueous leaf extract. However, this decrease was non-significant (P>0.05). In the group treated with aqueous leaf extract, CP activity increased significantly (P<0.05). LDH is found in the cells of almost all body tissues. Cellular injury in tissues containing LDH can result in its release has been associated with cardiac tissue damage and higher concentration of LDH could be a symptom of heart damage. Therefore, the decrease in LDH activity of the different aqueous extracts of *Hura crepitans* suggests that the extracts may protect against cardiac tissue damage.

**Table 4: ACTIVITIES OF CREATINE PHOSPHOKINASE (CPA) AND LACTATE DEHYDROGENASE (LDH) IN THE EXPERIMENTAL ANIMALS**
Table 5 shows the lipid profile of the different animal groups at the pre-induction stage. Total Cholesterol (TC), Triglycerides (TG), Low Density Lipoprotein-cholesterol (LDLC) and High Density Lipoprotein-Cholesterol (HDL) values indicate starting values in order to assess the effects of induction of hypertension and treatment.

**Table 5: LEVELS OF TOTAL CHOLESTEROL (Chol), TRIGLYCERIDES (TG), LOW DENSITY LIPOPROTEIN (HDL), LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDLC) AND VERY LOW DENSITY LIPOPROTEIN-CHOLESTEROL (VLDLC) AT THE PRE-INDUCTION STAGE.**

<table>
<thead>
<tr>
<th>Group</th>
<th>Pre-Induction</th>
<th>Post Induction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chol</td>
<td>TG</td>
</tr>
<tr>
<td>1</td>
<td>154.26±0.97</td>
<td>154.42±2.79</td>
</tr>
<tr>
<td>2</td>
<td>171.26±3.94</td>
<td>134.4±4.39</td>
</tr>
<tr>
<td>3</td>
<td>195.4±7.10</td>
<td>161.6±7.48</td>
</tr>
<tr>
<td>4</td>
<td>171.26±3.94</td>
<td>134.4±4.39</td>
</tr>
<tr>
<td>5</td>
<td>188.0±8.90</td>
<td>143.6±4.41</td>
</tr>
<tr>
<td>6</td>
<td>272.5±3.94</td>
<td>143.0±2.42</td>
</tr>
</tbody>
</table>

* The mean difference is significant at P< 0.05 level.

The values in the column were are expressed as mean ± S.E.M., n=5

The levels of these lipid biomolecules after treatment with the various aqueous plant extracts and propanolol are shown in Table 6. All the treated groups, showed a significant decrease in TG, VLDLC, and HDL when compared with the untreated hypertensive group. A significant decrease in TC was also recorded except in the group treated with aqueous bark extract whose decrease was non-significant when compared with the untreated hypertensive groups. This reduction in these hypertension bio indicators could be due to several factors. According to the work done by Adindu et al. (2015), *H.crepitians* parts (leaves, stem bark and roots) are very rich in phytochemicals such as flavonoids, carotenoids, alkaloids, lignans, etc. These phytochemicals such as Quercetin Isolflavoids, etc. have been shown to lower blood cholesterol level (Gebhardt, 1993; Kennedy, 1997; Hassel, 1998; Cook and Samman, 1996; Yan et al., 1995). The post-treatment values of these lipid biomolecules do not suggest very high risk conditions rather show hypotensive potentials (American Heart Association, 2009).
Plants have proved to have wide range of applications such as: food, source of raw materials, aesthetic value, environmentally friendly and for therapeutic purposes. In most developing countries, the use of plants as an alternative source of medicine has gained much ground due to the following reasons:

- Wide availability
- Cheap and affordable
- Little side effects
- Wide range of therapeutic applications
- Inadequate trained medical personnel and high cost of orthodox medicine

This study suggests that the various aqueous extracts of *Hura crepitans* have got profound hypotensive activity and this study has correlation with previously reported investigations using other plants. The mechanism by which *Hura crepitans* lowers blood is not yet fully established. However, it may be suggested that the hypotensive effect may be due to the stimulation of muscarinic receptors of the parasympathetic nerves by the compounds or the actions as an antagonist of $\alpha_2$ – adrenergic receptors or a beta – blocker or Ca$^{2+}$ channel blocker (Ameran, et al., 2004). The rich phytochemicals present in *Hura crepitans* suggests that the use of *Hura crepitans* as an antihypertensive agent may be useful.

There is the need to study the effect of dose on the efficacy of this herbal plant in the treatment of hypertension. This area is recommended for further study.

**REFERENCES**


20. Guiseppe, M; Fagard ,R; Narkiewicz, K; Kedom, J; Zanchetti, A; Bohm, M; Christaens ;T; Cifkova, R; De Backer, G; Dominiczak, A; Galertiess, M; Grobbec, D;E; Jaarsma T; Kirchhof, P; Nilsson ,P; M; Kjeldsen, SE; Laurett, S; Manolis A;S; Ruelope, L;M; Schneider ,R;E; Sirnes, P;A; Sleight P; Viigimaa, M; Waeber, B; Zannad ,F; Redon, J. (2013). “2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertention of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European heart journal 34(28): 2159-219.


